Preocupação Socioambiental e Hábitos de Consumo: o que nos dizem os estudantes universitários?

Este estudo teve como principal objetivo compreender os hábitos de consumo de estudantes de Administração da Universidade Federal de Pernambuco, campus Caruaru, para determinar o grau de preocupação socioambiental. Foram realizadas uma pesquisa bibliográfica e uma pesquisa de campo para avaliar em que medida esses estudantes tendem a expressar condutas que indiquem certa preocupação de ordem social e ambiental. Os resultados apontaram para um exíguo grau de preocupação socioambiental em relação aos seus hábitos de consumo, mas cabe destacar que o propósito desta pesquisa não foi o de generalizar os resultados, mas, sim, o de conhecer a estrutura de comportamentos responsáveis desses consumidores. Esta pesquisa contribui à medida que avalia esse comportamento de consumo, demonstrando que há pouca preocupação socioambiental por parte destes universitários. Ademais, contribui como um diagnóstico importante para assistir ações relacionadas às políticas públicas, ao demonstrar a necessidade de maior conscientização socioambiental desses estudantes

Análise histomorfométrica do fígado e pâncreas de três espécies de aves de rapina: Caracara plancus, Rupornis magnirostris e Coragyps atratus / Histomorphometric analysis of the liver and pancreas of three species of birds of prey: Caracara plancus, Rupornis magnirostris and Coragyps atratus

As aves de rapina Caracara plancus; Rupornis magnirostris e Coragyps atratus têm hábitos alimentares baseados em animais vivos ou mortos. Este estudo tem como objetivo realizar uma análise histomorfométrica descritiva do fígado e pâncreas de aves de rapina diunais encontradas em áreas urbanas e rurais. Esses órgãos foram coletados de sete animais, um de cada espécie, fixados em formol a 10%, processados e corados com hematoxilina e eosina (HE) para fígado e pâncreas e histoquímica em ácido de Schiff periódico (PAS) e prata de reticulina para fígado. As lâminas foram fotomicrografadas em microscópio óptico, a morfometria foi feita por meio do software ImageJ. Os dados foram analisados por meio dos testes estatísticos Kolmogorov Smirnov, Kruskal Wallis e Mann Whitney para comparar os resultados entre as espécies. As três espécies não variaram em relação à composição dos tecidos do pâncreas e do fígado, semelhante às descrições na literatura para outras espécies de aves. Na coloração PAS, os fígados das três espécies eram semelhantes, com baixa concentração de glicogênio. Na morfometria do fígado, foram observadas diferenças entre a área dos núcleos, o número total de núcleos, o número de células mononucleadas e binucleadas entre as três espécies. Quanto às fibras reticulares, quando comparadas entre si, as espécies C. plancus e R. magnisrostris não apresentaram diferenças, enquanto a espécie C. atratus diferiu das demais. As ilhotas pancreáticas também diferiram entre as espécies. Essas variações podem ser indicativas de adaptações do organismo aos diferentes hábitos alimentares

Avanços da cirurgia robotica no tratamento do Câncer

A cirurgia robótica tem sido almejada por profissionais cirurgiões, visto que, é um procedimento considerado de alta eficácia, assim como, apresenta reduzidos níveis de riscos ao paciente, o que configura significativamente a qualidade elevada do procedimento médico. Logo, tem sido utilizada no tratamento cirúrgico de diversos tipos de câncer, o qual tem demonstrado melhores resultados quando comparados com procedimentos mais invasivas ou tradicionais O principal objetivo do é discutir por meio de uma revisão sistematizada da literatura acerca dos avanços da cirurgia robótica no tratamento dos demais tipos de cânceres. O presente estudo trata-se de uma revisão sistemática da literatura, de modo que, realizou-se buscas de na Scielo, Periódico Capes e na Biblioteca Virtual em Saúde (BVS), através de termos específicos do Decs, o qual resultou-se em: “Neoplasias” AND “Procedimentos Cirúrgicos Robóticos” AND “Terapêutica”. Foram elegíveis um total de 8 estudos na presente revisão sistemática. Este procedimento é devidamente realizado com menores danos de incisão possível no paciente, de modo que, possibilitou a diminuição de dores pós-operatórios, além da redução de sangramentos, traumas, respostas inflamatórias, tempo de internação e até mesmo melhores resultados estéticos nos pacientes, quando comparados com os métodos mais tradicionais e invasivos

Síndrome do coração Pós-feriado: pacientes acometidos por arritmia cardíaca em detrimento do consumo exagerado de álcool: Post Holiday coração Syndrome: patients suffered by cardiac arrhythmia to the detriment of exaggerated alcohol consumption

INTRODUÇÃO: O álcool é conhecido por beneficiar o sistema cardiovascular com a ativação do sistema fibrinolítico, redução da agregação de plaquetas e aperfeiçoamento do perfil lipídico, entre outros mecanismos, quando consumido em doses moderadas. Todavia, seu uso de maneira abusiva culmina em patologias graves que podem evoluir para a morte, como a hipertensão arterial, a cardiomiopatia alcoólica, a arritmia cardíaca e até a “Síndrome do Coração Pós Feriado” ou do inglês, “Holiday Heart Syndrome”. OBJETIVOS: O presente estudo tem como objetivo delinear sobre a Síndrome do Coração Pós Feriado, transpassando por suas características clínicas, repercussões eletrofisiológicas, diagnóstico e manejo terapêutico. MATERIAIS E MÉTODOS: Dessa forma, o presente trabalho realizou uma revisão sistemática qualitativa, realizado no período entre julho e agosto de 2022, através de artigos das bases de dados Biblioteca Virtual em Saúde (BVS) e United States National Library of Medicine (PubMed). RESULTADOS E DISCUSSÃO: A interação do álcool no organismo está diretamente relacionada com o sistema nervoso autônomo do indivíduo, gerando um estado de desequilíbrio autonômico, assim há alterações elétricas, como acréscimo da frequência cardíaca, gerando um estado de taquicardia. A principal patologia encontrada em questão foi a taquicardia sinusal, sendo um tipo de arritmia e por conseguinte, notou-se a presença da fibrilação atrial, sendo o excesso no consumo de etanol é causador de aproximadamente 67% dos casos de emergências desta última enfermidade. CONCLUSÃO: Portanto, com base na literatura analisada, observou-se que a ingestão alcoólica aguda age retardando o sistema de condução cardíaco, atua no encurtamento do período refratário e o aumento da atividade simpática, além de aumentar os níveis de catecolaminas circulantes. Por fim, também se evidenciou uma associação entre álcool e fatores de risco, principalmente hipertensão e obesidade e essas patologias aumentam os episódios de fibrilação atrial

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017

Background: The Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) includes a comprehensive assessment of incidence, prevalence, and years lived with disability (YLDs) for 354 causes in 195 countries and territories from 1990 to 2017. Previous GBD studies have shown how the decline of mortality rates from 1990 to 2016 has led to an increase in life expectancy, an ageing global population, and an expansion of the non-fatal burden of disease and injury. These studies have also shown how a substantial portion of the world's population experiences non-fatal health loss with considerable heterogeneity among different causes, locations, ages, and sexes. Ongoing objectives of the GBD study include increasing the level of estimation detail, improving analytical strategies, and increasing the amount of high-quality data. Methods: We estimated incidence and prevalence for 354 diseases and injuries and 3484 sequelae. We used an updated and extensive body of literature studies, survey data, surveillance data, inpatient admission records, outpatient visit records, and health insurance claims, and additionally used results from cause of death models to inform estimates using a total of 68 781 data sources. Newly available clinical data from India, Iran, Japan, Jordan, Nepal, China, Brazil, Norway, and Italy were incorporated, as well as updated claims data from the USA and new claims data from Taiwan (province of China) and Singapore. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between rates of incidence, prevalence, remission, and cause of death for each condition. YLDs were estimated as the product of a prevalence estimate and a disability weight for health states of each mutually exclusive sequela, adjusted for comorbidity. We updated the Socio-demographic Index (SDI), a summary development indicator of income per capita, years of schooling, and total fertility rate. Additionally, we calculated differences between male and female YLDs to identify divergent trends across sexes. GBD 2017 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting. Findings: Globally, for females, the causes with the greatest age-standardised prevalence were oral disorders, headache disorders, and haemoglobinopathies and haemolytic anaemias in both 1990 and 2017. For males, the causes with the greatest age-standardised prevalence were oral disorders, headache disorders, and tuberculosis including latent tuberculosis infection in both 1990 and 2017. In terms of YLDs, low back pain, headache disorders, and dietary iron deficiency were the leading Level 3 causes of YLD counts in 1990, whereas low back pain, headache disorders, and depressive disorders were the leading causes in 2017 for both sexes combined. All-cause age-standardised YLD rates decreased by 3·9% (95% uncertainty interval [UI] 3·1-4·6) from 1990 to 2017; however, the all-age YLD rate increased by 7·2% (6·0-8·4) while the total sum of global YLDs increased from 562 million (421-723) to 853 million (642-1100). The increases for males and females were similar, with increases in all-age YLD rates of 7·9% (6·6-9·2) for males and 6·5% (5·4-7·7) for females. We found significant differences between males and females in terms of age-standardised prevalence estimates for multiple causes. The causes with the greatest relative differences between sexes in 2017 included substance use disorders (3018 cases [95% UI 2782-3252] per 100 000 in males vs 1400 [1279-1524] per 100 000 in females), transport injuries (3322 [3082-3583] vs 2336 [2154-2535]), and self-harm and interpersonal violence (3265 [2943-3630] vs 5643 [5057-6302]). Interpretation: Global all-cause age-standardised YLD rates have improved only slightly over a period spanning nearly three decades. However, the magnitude of the non-fatal disease burden has expanded globally, with increasing numbers of people who have a wide spectrum of conditions. A subset of conditions has remained globally pervasive since 1990, whereas other conditions have displayed more dynamic trends, with different ages, sexes, and geographies across the globe experiencing varying burdens and trends of health loss. This study emphasises how global improvements in premature mortality for select conditions have led to older populations with complex and potentially expensive diseases, yet also highlights global achievements in certain domains of disease and injury

Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.Hospital do Coracao (HCor) as part of the Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)'Brazilian Ministry of Healt

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials